IARTIntegra LifeSciences Holdings Corporation
Price
-4.9%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growth steady, the market undecided.
Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care. We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical (“CSS”) and Tissue Technologies (“TT”).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Integra LifeSciences Holdings Corporation (IART) reported revenue of $419M in Q2 2026 (quarter ended Jun 30, 2026), up 0.8% from the same quarter a year earlier. That came with a gross margin of 52% and net income of $4.5M (1.1% of revenue). For the full year FY2025, revenue was $1.64B (+1.5% year on year) and net income −$516M. Its largest product in Q2 2026 was Neurosurgery at $213M, 51% of the disclosed total, well ahead of Wound Reconstruction Solutions at 19%. The next results filing is expected around Jan 1, 2027, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 9, 2026Integra Announces Pricing of Senior Secured Notes.Regulation FD disclosure · press release
- Oct 2, 2026Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance.Earnings release · press release
- Jul 29, 2026Integra LifeSciences Reports Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $418.8MThe company’s own SEC segment disclosure.
- Neurosurgery$213.3M51%
- Wound Reconstruction Solutions$81.3M19%
- Surgical Instruments$54.8M13%
- ENT Solutions$41.2M10%
- Private Label$28.2M7%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.